瑞芬太尼用于成人无肌松药气管插管的系统评价与Meta分析
该系统评价纳入21项随机对照试验共1945例成人患者,比较瑞芬太尼与神经肌肉阻滞药用于气管插管的效果与安全性。瑞芬太尼(1.5-4.0 μg.kg-1)插管成功率与肌松药无差异(RR 0.97,95%CI 0.94-1.01,中等确定性证据),心动过缓和低血压风险亦无显著差异但证据确定性极低。结论认为瑞芬太尼可作为需避免肌松药时的插管替代药物。
要点
- 瑞芬太尼1.5-4.0 μg.kg-1插管成功率与肌松药相当,中等确定性证据支持。
- 瑞芬太尼2.0-4.0 μg.kg-1对优良插管条件无显著改善(RR 1.16,95%CI 0.72-1.87)。
- 心动过缓与低血压风险无显著差异,但证据确定性极低,需更多研究。
核心结论
- 瑞芬太尼可作为需避免神经肌肉阻滞药时成人气管插管的替代药物。
- 需更多研究评估不同剂量瑞芬太尼的血流动力学不良事件。
研究设计与样本
- 系统评价与Meta分析,纳入21项随机对照试验,共1945例成人患者。
主要发现
- 瑞芬太尼(1.5-4.0 μg.kg-1)与肌松药插管成功率无差异:RR 0.97(95%CI 0.94-1.01),6项研究1232例,I2 28%,p=0.16,中等确定性证据。
- 瑞芬太尼(2.0-4.0 μg.kg-1)优良插管条件与肌松药无差异:RR 1.16(95%CI 0.72-1.87),2项研究121例,I2 31%,p=0.54,中等确定性证据。
- 心动过缓:RR 0.44(95%CI 0.01-13.90),2项研究997例,I2 81%,p=0.64,证据确定性极低。
- 低血压:RR 1.05(95%CI 0.44-2.49),3项研究1071例,I2 92%,p=0.92,证据确定性极低。
临床怎么用
- 在肌松药应避免的成人插管场景中,可考虑瑞芬太尼1.5-4.0 μg.kg-1作为替代。
- 使用瑞芬太尼插管时需关注血流动力学不良事件,但现有证据确定性极低。
局限性
- 心动过缓和低血压结局的证据确定性极低。
- 需更多研究评估不同剂量瑞芬太尼的血流动力学不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is increasing interest in the use of short-acting opioids such as remifentanil to facilitate tracheal intubation. The aim of this systematic review was to determine the efficacy and safety of remifentanil for tracheal intubation compared with neuromuscular blocking drugs in adult patients. We conducted a systematic search for randomised controlled trials evaluating remifentanil for tracheal intubation. Primary outcomes included tracheal intubation conditions and adverse events. Twenty-one studies evaluating 1945 participants were included in the analysis. Use of remifentanil (1.5-4.0 μg.kg-1) showed no evidence of a difference in tracheal intubation success rate compared with neuromuscular blocking drugs (risk ratio (95%CI) 0.97 (0.94-1.01); six studies; 1232 participants; I2 28%; p = 0.16; moderate-certainty evidence). Compared with neuromuscular blocking drugs, the use of remifentanil (2.0-4.0 μg.kg-1) makes little to no difference in terms of producing excellent tracheal intubation conditions (risk ratio (95%CI) 1.16 (0.72-1.87); two studies; 121 participants; I2 31%, p = 0.54; moderate-certainty of evidence). There was no evidence of an effect between remifentanil (2.0-4.0 μg.kg-1) and neuromuscular blocking drugs for bradycardia (risk ratio (95%CI) 0.44 (0.01-13.90); two studies; 997 participants; I2 81%; p = 0.64) and hypotension (risk ratio (95%CI) 1.05 (0.44-2.49); three studies; 1071 participants; I2 92%; p = 0.92). However, the evidence for these two outcomes was judged to be of very low-certainty. We conclude that remifentanil may be used as an alternative drug for tracheal intubation in cases where neuromuscular blocking drugs are best avoided, but more studies are required to evaluate the haemodynamic adverse events of remifentanil at different doses.
引用
- Santos L, Zheng H, Singhal S, et al. Remifentanil for tracheal intubation without neuromuscular blocking drugs in adult patients: a systematic review and meta-analysis. Anaesthesia. 2024. PMID: 38403817. doi:10.1111/anae.16255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。